<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">444</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2022-9-2-105-110</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Primary mediastinal large B-cell lymphoma with a rare <italic>ALK</italic> gene mutation</article-title><trans-title-group xml:lang="ru"><trans-title>Первичная медиастинальная В-крупноклеточная лимфома с редкой мутацией в гене <italic>ALK</italic></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3061-6108</contrib-id><name-alternatives><name xml:lang="en"><surname>Kit</surname><given-names>O. I.</given-names></name><name xml:lang="ru"><surname>Кит</surname><given-names>О. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3001-0675</contrib-id><name-alternatives><name xml:lang="en"><surname>Kamaeva</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Камаева</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Inna Anatolyevna Kamaeva</bold></p><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p><bold>Инна Анатольевна Камаева</bold></p><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p><p> </p></bio><email>inkamaeva@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4457-3815</contrib-id><name-alternatives><name xml:lang="en"><surname>Lysenko</surname><given-names>I. B.</given-names></name><name xml:lang="ru"><surname>Лысенко</surname><given-names>И. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Novikova</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Новикова</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Timoshkina</surname><given-names>N. N.</given-names></name><name xml:lang="ru"><surname>Тимошкина</surname><given-names>Н. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7224-3106</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikolaeva</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Николаева</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gaisultanova</surname><given-names>Ya. S.</given-names></name><name xml:lang="ru"><surname>Гайсултанова</surname><given-names>Я. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0843-6012</contrib-id><name-alternatives><name xml:lang="en"><surname>Khamaneva</surname><given-names>N. Yu.</given-names></name><name xml:lang="ru"><surname>Саманева</surname><given-names>Н. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2385-6285</contrib-id><name-alternatives><name xml:lang="en"><surname>Pushkin</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Пушкин</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th </sup>Liniya St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14‑я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2022</year></pub-date><volume>9</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>105</fpage><lpage>110</lpage><history><date date-type="received" iso-8601-date="2022-06-26"><day>26</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-06-26"><day>26</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Kit O.I., Kamaeva I.A., Lysenko I.B., Novikova I.A., Timoshkina N.N., Nikolaeva N.V., Gaisultanova Y.S., Khamaneva N.Y., Pushkin A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Кит О.И., Камаева И.А., Лысенко И.Б., Новикова И.А., Тимошкина Н.Н., Николаева Н.В., Гайсултанова Я.С., Саманева Н.Ю., Пушкин А.А.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Kit O.I., Kamaeva I.A., Lysenko I.B., Novikova I.A., Timoshkina N.N., Nikolaeva N.V., Gaisultanova Y.S., Khamaneva N.Y., Pushkin A.A.</copyright-holder><copyright-holder xml:lang="ru">Кит О.И., Камаева И.А., Лысенко И.Б., Новикова И.А., Тимошкина Н.Н., Николаева Н.В., Гайсултанова Я.С., Саманева Н.Ю., Пушкин А.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/444">https://umo.abvpress.ru/jour/article/view/444</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Primary mediastinal large B-cell lymphoma is an aggressive variant of lymphoma characterized by genetic heterogeneity. First-time therapy for primary mediastinal large B-cell lymphoma usually includes immunochemotherapy. However, a substantial proportion of patients do not respond to this therapy.</p><p><bold>Objective</bold> – to analyze clinical characteristics of primary refractory primary mediastinal large B-cell lymphoma taking into account the results of targeted next-generation sequencing (NGS).</p><p><bold>Materials and methods.</bold> A 22‑year-old patient with primary mediastinal large B-cell lymphoma who had not responded to immunochemotherapy was tested using targeted NGS for 77 genes.</p><p><bold>Results.</bold> We identified 2 rare mutations in the ALK gene with an unclear clinical value. According to the literature, these mutations are primarily found in solid tumors.</p><p><bold>Conclusion.</bold> Missense mutations identified in the ALK gene are presumably associated with the course of primary mediastinal large B-cell lymphoma, in particular, with primary refractory disease.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Первичная медиастинальная В-крупноклеточная лимфома представляет собой агрессивный вариант лимфомы, характеризующийся генетической гетерогенностью. В 1-й линии лечения данной патологии принято проводить иммунохимиотерапию. Однако, несмотря на успехи в лечении первичной медиастинальной B-крупноклеточной лимфомы, есть большая группа пациентов, рефрактерных к терапии.</p><p><bold>Цель исследования</bold> – оценка особенностей клинического течения первично рефрактерной первичной медиастинальной В-крупноклеточной лимфомы с учетом данных таргетного секвенирования нового поколения (next generation sequencing, NGS).</p><p><bold>Материалы и методы.</bold> Пациентке, 22 лет, с первичной медиастинальной В-крупноклеточной лимфомой, у которой не наблюдалось эффекта от иммунохимиотерапии, выполнено таргетное секвенирование нового поколения с использованием панели из 77 генов.</p><p><bold>Результаты.</bold> В ходе таргетного секвенирования нового поколения выявлены 2 редких варианта мутаций в гене ALK с неясным клиническим значением. Согласно данным литературы они встречаются преимущественно в солидных опухолях.</p><p><bold>Заключение.</bold> Выявленные миссенс-мутации в гене ALK, возможно, связаны с особенностью течения первичной медиастинальной В-крупноклеточной лимфомы, в частности с первичной рефрактерностью к проводимому лечению.</p></trans-abstract><kwd-group xml:lang="en"><kwd>primary mediastinal large B-cell lymphoma</kwd><kwd>targeted next-generation sequencing</kwd><kwd>primary refractory disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>первичная медиастинальная В-крупноклеточная лимфома</kwd><kwd>таргетное секвенирование нового поколения</kwd><kwd>первично рефрактерное течение заболевания</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Arkhipova O.E., Chernogubova E.A., Tarasov V.A. et al. The level of oncological diseases as an indicator of the medical and environmental safety of territories (on the example of the Rostov region). Vestnik Yuzhnogo nauchnogo centra RAN = Bulletin of the Southern Scientific Center of the Russian Academy of Sciences 2013;9(3):7–14. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Архипова О.Е., Черногубова Е.А., Тарасов В.А. и др. Уровень онкологических заболеваний как индикатор медико-экологической безопасности территорий (на примере Ростовской области). Вестник Южного научного центра РАН 2013;9(3):7–14.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kamaeva I.A., Lysenko I.B., Nikolaeva N.V. et al. The use of immunotherapy for the treatment of refractory forms of Hodgkin’s lymphoma in real clinical practice. Yuzhno-Rossijskij onkologicheskij zhurnal = South Russian Journal of Oncology 2021;2(2):34–41. (In Russ.). DOI: 10.37748/2686-9039-2021-2-2-4.</mixed-citation><mixed-citation xml:lang="ru">Камаева И.А., Лысенко И.Б., Николаева Н.В. и др. Применение иммунотерапии для лечения рефрактерных форм лимфомы Ходжкина в реальной клинической практике. Южно-Российский онкологический журнал 2021;2(2): 34–41.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Li M.M., Datto M., Duncavage E.J. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 2017;19(1):4–23. DOI: 10.1016/j.jmoldx.2016.10.002.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Taghizadeh H., Müllauer L., Mader R.M., Schindl M., Prager G.W. Applied precision medicine in metastatic pancreatic ductal adenocarcinoma. Ther Adv Med Oncol 2020;12:1758835920938611. DOI: 10.1177/1758835920938611.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>NCBI. ALK receptor tyrosine kinase [Homo sapiens (human)]. Available at: https://www.ncbi.com.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wang H., Wang Z., Zhang G. et al. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Cancer Med 2020;9(2):487–95. DOI: 10.1002/cam4.2706.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Majewska H., Gorczyński A., Czapiewski P. et al. ALK alterations in salivary gland carcinomas. Virchows Arch 2021;478(5):933–41. DOI: 10.1007/s00428-020-02971-w.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>ALK Pathway. Gene Set Enrichment Analysis. Available at: https://www.gseamsigdb.org/gsea/index.jsp.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Genetics illustrations. Smart Servier Medical Art.Available at: https://smart.servier.com/category/cellular-biology/genetics/.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ronchi A., Montella M., Cozzolino I. et al. The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors. Eur Rev Med Pharmacol Sci 2020;24(7):3829–38. DOI: 10.26355/eurrev_202004_20849.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kazlouskaya V., Ho J., Jedrych J., Karunamurthy A. Spindle cell variant of epithelioid cell histiocytoma (spindle cell histiocytoma) with ALK gene fusions: cases series and review of the literature. J Cutan Pathol 2021;48(7):837–41. DOI: 10.1111/cup.13923.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Yang C., Zhang L., Love-Gregory L. et al. Identification of novel ALK rearrangements in gynecologic clear cell carcinoma. Int J Cancer 202115;148(2):459–68. DOI: 10.1002/ijc.33330.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Fetahu I.S., Taschner-Mandl S. Neuroblastoma and the epigenome. Cancer Metastasis Rev 2021;40(1):173–89. DOI: 10.1007/s10555-020-09946-y.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Berry T., Luther W., Bhatnagar N. et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012;22(1):117–30. DOI: 10.1016/j.ccr.2012.06.001.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Umapathy G., Mendoza-Garcia P., Hallberg B., Palmer R.H. Targeting anaplastic lymphoma kinase in neuroblastoma. APMIS 2019;127(5):288–302. DOI: 10.1111/apm.12940.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Mossé Y.P., Laudenslager M., Longo L. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455(7215):930–5. DOI: 10.1038/nature07261.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Mlakar V., Morel E., Mlakar S.J. et al. A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma. J Exp Clin Cancer Res 2021;40(1):189. DOI: 10.1186/s13046-021-01967-x.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Louis D.N., Perry A., Reifenberger G. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary Acta Neuropathol 2016;131:803–20. DOI: 10.1007/s00401-016-1545-1.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Hadjadj J., Castro C.N., Tusseau M. et al. Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun 2020;11(1):5341. DOI: 10.1038/s41467-020-18925-4.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Chapuy B., Stewart C., Dunford A.J. et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood 2019;134(26):2369–82. DOI: 10.1182/blood.2019002067.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Dubois S., Viailly P.J., Mareschal S. et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res 2016;22(12):2919–28. DOI: 10.1158/1078-0432.CCR-15-2305.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Zhou H., Xu-Monette Z.Y., Xiao L. et al. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J 2020;10(5):49. DOI: 10.1038/s41408-020-0312-7.</mixed-citation></ref></ref-list></back></article>
